[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112016020895A2 - Hepatitis B Core Allosteric Protein Modulators - Google Patents

Hepatitis B Core Allosteric Protein Modulators

Info

Publication number
BR112016020895A2
BR112016020895A2 BR112016020895A BR112016020895A BR112016020895A2 BR 112016020895 A2 BR112016020895 A2 BR 112016020895A2 BR 112016020895 A BR112016020895 A BR 112016020895A BR 112016020895 A BR112016020895 A BR 112016020895A BR 112016020895 A2 BR112016020895 A2 BR 112016020895A2
Authority
BR
Brazil
Prior art keywords
hepatitis
core
protein modulators
allosteric protein
allosteric
Prior art date
Application number
BR112016020895A
Other languages
Portuguese (pt)
Other versions
BR112016020895B1 (en
Inventor
Zlotnick Adam
Maag Hans
Daniel Arnold Lee
w turner William
Original Assignee
Assembly Biosciences Inc
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assembly Biosciences Inc, Univ Indiana Res & Tech Corp filed Critical Assembly Biosciences Inc
Priority claimed from PCT/US2015/020444 external-priority patent/WO2015138895A1/en
Publication of BR112016020895A2 publication Critical patent/BR112016020895A2/en
Publication of BR112016020895B1 publication Critical patent/BR112016020895B1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se, em parte, a compostos tendo propriedades efetoras alostéricas contra cp do vírus da hepatite b. são também providos aqui métodos de tratamento de infecções virais, tal como hepatite b, compreendendo administrar a um paciente com necessidade do mesmo um composto revelado.The present invention relates in part to compounds having allosteric effector properties against hepatitis b virus cp. Also provided herein are methods of treating viral infections, such as hepatitis b, comprising administering to a patient in need thereof a disclosed compound.

BR112016020895-1A 2014-03-13 2015-03-13 HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS, THEIR USES, AND PHARMACEUTICAL COMPOSITION BR112016020895B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461952467P 2014-03-13 2014-03-13
US61/952,467 2014-03-13
US201461010025P 2014-06-10 2014-06-10
US61/010,025 2014-06-10
PCT/US2015/020444 WO2015138895A1 (en) 2014-03-13 2015-03-13 Hepatitis b core protein allosteric modulators

Publications (2)

Publication Number Publication Date
BR112016020895A2 true BR112016020895A2 (en) 2017-10-10
BR112016020895B1 BR112016020895B1 (en) 2023-02-07

Family

ID=62620471

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016020895-1A BR112016020895B1 (en) 2014-03-13 2015-03-13 HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS, THEIR USES, AND PHARMACEUTICAL COMPOSITION

Country Status (1)

Country Link
BR (1) BR112016020895B1 (en)

Also Published As

Publication number Publication date
BR112016020895B1 (en) 2023-02-07

Similar Documents

Publication Publication Date Title
PH12018500571A1 (en) Hepatitis b core protein modulators
MX2019003525A (en) Hepatitis b core protein allosteric modulators.
MX2023013140A (en) Vaccines against hepatitis b virus.
NZ730809A (en) Methods for treating filoviridae virus infections
PH12016500486A1 (en) Aza-pyridone compounds and uses thereof
MX2016013689A (en) 4-amino-imidazoquinoline compounds.
NZ631726A (en) Therapeutic compounds for the treatment of viral infections
BR112018009009A8 (en) combined therapy of an hbv capsid formation inhibitor and an interferon
MD20140035A2 (en) Method for treating hepatitis C virus
EP3474863A4 (en) Phosphoramidates for the treatment of hepatitis b virus
PH12016500492A1 (en) Pyridazinone compounds and uses thereof
PH12019500513A1 (en) Mast cell stabilizers for treatment of hypercytokinemia and viral infection
CY1124345T1 (en) COMPLEXES OF POLYPEPTIDE-HELICAL OLIGONUCLEOTIDE COMPLEXES AND METHODS
MX2017000312A (en) Isoindoline derivatives for use in the treatment of a viral infection.
CY1119957T1 (en) TREATMENT OF PATIENTS WITH THE USE OF ANNOUNCED PHARMACEUTICAL PREPARATION
JO3281B1 (en) Benzofuran Compounds for the Treatment of Hepatitis C Virus Infections
EA201590297A1 (en) HETEROCYCLIC CARBOXAMIDES FOR THE TREATMENT OF VIRAL DISEASES
MX360137B (en) H5 proteins of h5n1 influenza virus for use as a medicament.
BR112016020895A2 (en) Hepatitis B Core Allosteric Protein Modulators
EA201691835A1 (en) ALLASTERIC MODULATORS OF CAPSIDE PROTEIN OF HEPATITIS B
TH1601005264A (en)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 43/00 , A61K 31/55 , C07D 498/00

Ipc: C07D 498/00 (2006.01), A61K 31/55 (2006.01), A61P

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) ; ASSEMBLY BIOSCIENCES, INC. (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/03/2015, OBSERVADAS AS CONDICOES LEGAIS